Smith, Moore & Co’s iShares Biotechnology ETF IBB Stock Holding History

Smith, Moore & Co’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$837K	Buy	4,954 +279	+6%	+$47.7K	0.06%	239
2025 Q4	$789K	Hold	4,675	–	–	0.06%	239
2025 Q3	$675K	Sell	4,675 -260	-5%	-$35.5K	0.05%	269
2025 Q2	$624K	Sell	4,935 -175	-3%	-$21.5K	0.05%	271
2025 Q1	$654K	Sell	5,110 -50	-1%	-$6.78K	0.06%	254
2024 Q4	$682K	Hold	5,160	–	–	0.06%	248
2024 Q3	$751K	Sell	5,160 -100	-2%	-$14.5K	0.07%	225
2024 Q2	$722K	Buy	5,260 +159	+3%	+$21.2K	0.07%	216
2024 Q1	$700K	Sell	5,101 -199	-4%	-$27.2K	0.07%	220
2023 Q4	$672K	Sell	5,300 -1,251	-19%	-$153K	0.08%	211
2023 Q3	$759K	Sell	6,551 -90	-1%	-$11.4K	0.1%	181
2023 Q2	$799K	Buy	6,641 +329	+5%	+$42.7K	0.1%	183
2023 Q1	$815K	Sell	6,312 -25	-0.4%	-$3.27K	0.11%	173
2022 Q4	$832K	Sell	6,337 -25	-0.4%	-$3.23K	0.12%	171
2022 Q3	$744K	Buy	6,362 +201	+3%	+$25K	0.11%	170
2022 Q2	$725K	Hold	6,161	–	–	0.11%	180
2022 Q1	$803K	Sell	6,161 -80	-1%	-$10.4K	0.11%	186
2021 Q4	$953K	Buy	6,241 +155	+3%	+$24K	0.13%	160
2021 Q3	$984K	Buy	6,086 +443	+8%	+$74.6K	0.15%	138
2021 Q2	$971K	Sell	5,643 -688	-11%	-$106K	0.15%	146
2021 Q1	$953K	Buy	6,331 +736	+13%	+$117K	0.15%	139
2020 Q4	$795K	Sell	5,595 -204	-4%	-$29.2K	0.15%	133
2020 Q3	$785K	Hold	5,799	–	–	0.16%	122
2020 Q2	$745K	Buy	5,799 +325	+6%	+$41.4K	0.16%	113
2020 Q1	$590K	Buy	5,474 +260	+5%	+$29.9K	0.16%	131
2019 Q4	$628K	Sell	5,214 -400	-7%	-$44.6K	0.13%	148
2019 Q3	$559K	Buy	5,614 +71	+1%	+$7.43K	0.12%	157
2019 Q2	$605K	Buy	5,543 +400	+8%	+$42.5K	0.14%	146
2019 Q1	$614K	Buy	5,143 +5	+0.1%	+$548	0.15%	143
2018 Q4	$496K	Sell	5,138 -586	-10%	-$62.2K	0.13%	154
2018 Q3	$698K	Buy	5,724 +1,296	+29%	+$153K	0.16%	130
2018 Q2	$486K	Buy	4,428 +247	+6%	+$26.4K	0.12%	160
2018 Q1	$446K	Buy	4,181 +759	+22%	+$84.1K	0.12%	170
2017 Q4	$365K	Buy	3,422 +5	+0.1%	+$534	0.1%	198
2017 Q3	$380K	Buy	3,417 +6	+0.2%	+$641	0.11%	194
2017 Q2	$353K	Buy	3,411 +276	+9%	+$27.2K	0.12%	171
2017 Q1	$306K	Buy	3,135 +66	+2%	+$6.32K	0.11%	182
2016 Q4	$271K	Buy	3,069 +996	+48%	+$90.6K	0.1%	181
2016 Q3	$200K	Buy	+2,073	New	+$197K	0.08%	204

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Smith, Moore & Co's IBB Position: Q1 2026 in Review

Smith, Moore & Co increased its iShares Biotechnology ETF (IBB) stake by 6% in Q1 2026, buying an estimated $47.7K and bringing the position to 4,954 shares worth $837K. The position accounts for 0.06% of the portfolio, ranked #239.

Smith, Moore & Co first reported a position in IBB in Q3 2016 and has held it in 39 quarters since. The position peaked at $984K in Q3 2021. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Smith, Moore & Co held 4,954 shares of iShares Biotechnology ETF worth $837K as of Q1 2026.
Smith, Moore & Co bought 279 iShares Biotechnology ETF shares in Q1 2026, an estimated $47.7K.
iShares Biotechnology ETF made up 0.06% of Smith, Moore & Co's portfolio in Q1 2026, its #239 holding.
Smith, Moore & Co first reported a position in iShares Biotechnology ETF in Q3 2016 and has held it in 39 quarters since.
Smith, Moore & Co's iShares Biotechnology ETF position peaked at $984K in Q3 2021.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.